Gyre Therapeutics Announces 2024 Annual Meeting of Stockholders on June 12, 2024
Ticker: GYRE · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Gyre Therapeutics, Annual Meeting, Proxy Statement, Stockholders, Corporate Governance
TL;DR
<b>Gyre Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on director elections, executive compensation, auditor ratification, and charter amendments.</b>
AI Summary
GYRE THERAPEUTICS, INC. (GYRE) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Gyre Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 10:00 a.m. Pacific Time. The meeting will be conducted virtually via live audio webcast at www.virtualshareholdermeeting.com/GYRE2024. Key agenda items include electing three Class III director nominees, approving executive compensation, and ratifying the appointment of Grant Thornton Zhitong Certified Public Accountants LLP. Stockholders will also vote on an amendment to the Certificate of Incorporation regarding officer exculpation. The record date for determining stockholders entitled to vote is April 18, 2024.
Why It Matters
For investors and stakeholders tracking GYRE THERAPEUTICS, INC., this filing contains several important signals. The annual meeting is a critical forum for shareholders to exercise their voting rights on corporate governance matters, including the election of directors and executive compensation. The ratification of the independent auditor and proposed amendments to the Certificate of Incorporation are key decisions that impact the company's financial oversight and legal structure.
Risk Assessment
Risk Level: low — GYRE THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy materials to make informed voting decisions on director nominees, executive compensation, auditor ratification, and proposed charter amendments.
Key Numbers
- 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
- June 12 — Annual Meeting Date (Annual Meeting will be held on Wednesday, June 12, 2024)
- 10:00 a.m. Pacific Time — Annual Meeting Time (at 10:00 a.m. Pacific Time)
- April 18, 2024 — Record Date (April 18, 2024 as the Record Date)
- 3 — Director Nominees (elect the three Class III director nominees)
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — Registrant
- Grant Thornton Zhitong Certified Public Accountants LLP (company) — independent registered public accounting firm
- June 12, 2024 (date) — Annual Meeting date
- April 18, 2024 (date) — Record Date
- 10:00 a.m. Pacific Time (time) — Annual Meeting time
- Class III (other) — director nominees
FAQ
When did GYRE THERAPEUTICS, INC. file this DEF 14A?
GYRE THERAPEUTICS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by GYRE THERAPEUTICS, INC. (GYRE).
Where can I read the original DEF 14A filing from GYRE THERAPEUTICS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by GYRE THERAPEUTICS, INC..
What are the key takeaways from GYRE THERAPEUTICS, INC.'s DEF 14A?
GYRE THERAPEUTICS, INC. filed this DEF 14A on April 29, 2024. Key takeaways: Gyre Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 10:00 a.m. Pacific Time.. The meeting will be conducted virtually via live audio webcast at www.virtualshareholdermeeting.com/GYRE2024.. Key agenda items include electing three Class III director nominees, approving executive compensation, and ratifying the appointment of Grant Thornton Zhitong Certified Public Accountants LLP..
Is GYRE THERAPEUTICS, INC. a risky investment based on this filing?
Based on this DEF 14A, GYRE THERAPEUTICS, INC. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading GYRE THERAPEUTICS, INC.'s DEF 14A?
Stockholders should review the proxy materials to make informed voting decisions on director nominees, executive compensation, auditor ratification, and proposed charter amendments. The overall sentiment from this filing is neutral.
Risk Factors
- Officer Exculpation Amendment [medium — regulatory]: The proposed amendment to the Certificate of Incorporation aims to reflect Delaware law provisions regarding officer exculpation, which could impact director and officer liability.
Key Dates
- 2024-06-12: 2024 Annual Meeting of Stockholders — Key date for voting on corporate matters.
- 2024-04-18: Record Date — Determines which stockholders are eligible to vote.
Glossary
- DEF 14A
- Definitive Proxy Statement filed with the SEC. (This filing type indicates the company is providing final proxy materials to shareholders for a meeting.)
- Proxy Statement
- A document providing information to shareholders about matters to be voted on at a company meeting. (Essential for shareholders to understand proposals and make informed voting decisions.)
- Record Date
- A specific date used to determine which shareholders are entitled to receive notice of and vote at a shareholder meeting. (Crucial for identifying eligible voters for the annual meeting.)
- Officer Exculpation
- Provisions in a company's charter that limit or eliminate the personal liability of officers for certain breaches of fiduciary duty. (Relevant to the proposed amendment to the Certificate of Incorporation, impacting officer liability.)
Filing Stats: 4,471 words · 18 min read · ~15 pages · Grade level 13 · Accepted 2024-04-29 08:46:38
Filing Documents
- ny20022295x2_def14a.htm (DEF 14A) — 537KB
- logo_gyre.jpg (GRAPHIC) — 26KB
- ny20022295x2_pc01x1.jpg (GRAPHIC) — 641KB
- ny20022295x2_pc02x1.jpg (GRAPHIC) — 685KB
- ny20022295x2_pvp01.jpg (GRAPHIC) — 141KB
- ny20022295x2_pvp02.jpg (GRAPHIC) — 146KB
- 0001140361-24-022721.txt ( ) — 2794KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 24 CERTAIN INFORMATION ABOUT OUR COMMON STOCK ​ ​ 32 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS ​ ​ 34 OTHER MATTERS ​ ​ 35 LEGAL MATTERS Business Combination. On October 30, 2023 (the “Business Combination Closing”), we completed a business combination pursuant to a Business Combination Agreement, dated as of December 26, 2022, as amended (the “Business Combination Agreement”), by and among the Company, GNI USA, Inc., a Delaware corporation (“GNI USA”), GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“GNI Japan”), GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability (“GNI Hong Kong”), Shanghai Genomics, Inc., a company organized under the laws of the People’s Republic of China (“Shanghai Genomics”), the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares (such transactions contemplated by the Business Combination Agreement, collectively, the “Business Combination”). In connection with the Business Combination Closing, we changed our name from “Catalyst Biosciences, Inc.” to “Gyre Therapeutics, Inc.” and our Nasdaq ticker symbol from “CBIO” to “GYRE”. Important Notice Regarding the Availability of Proxy Materials for the 2024 Annual Meeting of Stockholders to Be Held on June 12, 2024. The Proxy Statement and Annual Report for the year ended December 31, 2023 are available at www.proxyvote.com . Forward-Looking Statements. The Proxy Statement may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subjec